Compare Amgen, Inc. (AMGN) vs Corsair Gaming Inc (CRSR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amgen, Inc. vs Corsair Gaming Inc — how do they compare? Amgen, Inc. trades at $357 (market cap $196.12B), while Corsair Gaming Inc trades at $9.32 (market cap $1.03B). The key difference: Amgen, Inc. is far larger — about 190.4× Corsair Gaming Inc's market cap, and Amgen, Inc. pays a 2.77% dividend while Corsair Gaming Inc pays none. Which is the better fit depends on your goals.
| AMGN | CRSR | |
|---|---|---|
Market Cap | $196.12B | $1.03B |
Sector | Health | Technology |
52-Week High | $388.16 | $12.14 |
52-Week Low | $271.18 | $4.58 |
Enterprise Value | $241.41B | $1.10B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Corsair Gaming (CRSR) trades at $9.66, up 1.15% with a bullish technical outlook. The stock shows mixed fundamentals with a high P/E ratio of 107.33 but attractive P/S of 0.71, while recent earnings beats and new AI product launches drive optimism. Revenue remains stable around $1.5B, though profitability is inconsistent with a net margin of just 0.49%.
Corsair presents a speculative opportunity with strong product innovation but faces execution risks. Analyst consensus is cautious with a $9 price target below current levels. The company's pivot to AI hardware and gaming partnerships offers growth potential, but thin margins and competitive pressures require careful monitoring for sustained profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Corsair Gaming Inc
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →
